Table 1 Patient characteristics Patient... | American Society of Hematology

Table 1

Patient characteristics

Patient	Disease	Sex	Age at allo-SCT (years)	Conditioning regimen	CMV status R/D*	Sample (days)†	CD8⁺ T cells				Antigen-specific T cells
Patient	Disease	Sex	Age at allo-SCT (years)	Conditioning regimen	CMV status R/D*	Sample (days)†	T_n (%)	T_scm (%)	T_cm (%)	T_em (%)	Antigen	Frequency (%)‡	T_n (%)	T_scm (%)	T_cm (%)	T_em (%)
1	NHL	F	48	Cy + Ida + TBI	NA	264	0.14	0.06	2.72	97.08	—	—	—	—	—	—
2	CML	M	47	Cy + Bus	+/+	172	1.45	0.19	0.65	97.70	CMV.HLA-B7	4.86	0.01	0.01	0.13	99.85
3	AML	M	50	Cy + Ida + TBI	+/+	68	0.01	<0.01	0.16	99.82	CMV.HLA-B7	27.51	ND	ND	0.18	99.82
4	MM	M	59	Cy + Flu	–/+	63	0.03	0.01	0.15	99.81	CMV.HLA-B7	10.69	ND	ND	0.12	99.88
5	AML	M	50	Cy + Ida + TBI	+/–	205	0.46	0.68	1.20	97.65	CMV.HLA-B7	9.91	0.02	0.05	0.27	99.67
6	AML	M	40	Cy + TBI	+/–	79	0.07	0.10	2.50	97.33	CMV.HLA-A2	0.28	0.97	0.97	5.91	92.16
7	AML	M	60	Cy + Ida + TBI	NA	90	0.17	0.04	1.04	98.75	HY.HLA-B7	0.50	ND	ND	4.09	95.91
8	AML	M	26	Cy + Ida + TBI	NA	104	0.54	0.02	2.15	97.30	HY.HLA-A2	0.45	ND	ND	ND	100.00
9	NHL	M	28	Cy + Ida + TBI	NA	196	3.40	0.16	11.99	84.45	HY.HLA-A2	0.19	ND	ND	8.41	91.59

Patient	Disease	Sex	Age at allo-SCT (years)	Conditioning regimen	CMV status R/D*	Sample (days)†	CD8⁺ T cells				Antigen-specific T cells
Patient	Disease	Sex	Age at allo-SCT (years)	Conditioning regimen	CMV status R/D*	Sample (days)†	T_n (%)	T_scm (%)	T_cm (%)	T_em (%)	Antigen	Frequency (%)‡	T_n (%)	T_scm (%)	T_cm (%)	T_em (%)
1	NHL	F	48	Cy + Ida + TBI	NA	264	0.14	0.06	2.72	97.08	—	—	—	—	—	—
2	CML	M	47	Cy + Bus	+/+	172	1.45	0.19	0.65	97.70	CMV.HLA-B7	4.86	0.01	0.01	0.13	99.85
3	AML	M	50	Cy + Ida + TBI	+/+	68	0.01	<0.01	0.16	99.82	CMV.HLA-B7	27.51	ND	ND	0.18	99.82
4	MM	M	59	Cy + Flu	–/+	63	0.03	0.01	0.15	99.81	CMV.HLA-B7	10.69	ND	ND	0.12	99.88
5	AML	M	50	Cy + Ida + TBI	+/–	205	0.46	0.68	1.20	97.65	CMV.HLA-B7	9.91	0.02	0.05	0.27	99.67
6	AML	M	40	Cy + TBI	+/–	79	0.07	0.10	2.50	97.33	CMV.HLA-A2	0.28	0.97	0.97	5.91	92.16
7	AML	M	60	Cy + Ida + TBI	NA	90	0.17	0.04	1.04	98.75	HY.HLA-B7	0.50	ND	ND	4.09	95.91
8	AML	M	26	Cy + Ida + TBI	NA	104	0.54	0.02	2.15	97.30	HY.HLA-A2	0.45	ND	ND	ND	100.00
9	NHL	M	28	Cy + Ida + TBI	NA	196	3.40	0.16	11.99	84.45	HY.HLA-A2	0.19	ND	ND	8.41	91.59

AML, acute myeloid leukemia; Bus, busulphan; CML, chronic myeloid leukemia; Cy, cyclophosphamide; D, donor; F, female; Ida, idarubicin; M, male; MM, multiple myeloma; NA, not applicable; ND, not detectable; NHL, non-Hodgkin lymphoma; R, recipient; TBI, total body irradiation.

Cytomegalovirus status of recipient and donor prior to allo-SCT. All 5 studied patients had no active CMV infection at time of sampling after allo-SCT.

†

Sample, time of sample collection in days after allo-SCT

‡

Frequency, percentage of tetramer⁺ cells within CD8⁺ T cell population.

View Large

This Feature Is Available To Subscribers Only